Overview

Liposomal Bupivacaine in Vaginal Hysterectomy

Status:
Terminated
Trial end date:
2021-07-23
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the effects of preemptive analgesia using liposomal bupivacaine mixed with bupivacaine HCl, versus bupivacaine HCl alone for uterosacral ligament injection in patients undergoing vaginal hysterectomy. We hypothesize that the group receiving a combination of liposomal bupivacaine and bupivacaine HCl will report superior postoperative pain management. Enhancement in pain control should confer a decrease in opioid and other analgesic medication requirements, which may contribute to decreased nausea, vomiting, and higher overall patient satisfaction with pain control.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine